Mitochondrial Disease and Specialties - Part 2

Mitochondrial Disease and Specialties - Part 2

Mitochondrial Disease and Specialties - Part 2

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Vesicular Transfer; Nanotube Transfer; Mito Transfer & Leigh Syndrome; Mito Transplantation; mtFASII Pathway & Mouse Model; Mito FASII in OXPHOS; Small Molecule Therapy

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Step Toward Treatment of Mito Cardiomyopathy; mtDNA Gene Editing; mtDNA & Deaminases

Mito & Cellular Metabolism; mtDNA Conformation Regulation; MNRR1 Bicompartmental Mito Regulation; MAT (Mito Augmentation Therapy and MEPAN;

Mito-DNA Encoded Microproteins; mtDNA Transcription Factor Binding; Stem Cells, Organoids & Imaging; mtDNA Haplogroup Disease Associations

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Mitochondrial Double-Stranded RNA as a New DAMP to Activate the Immune Response in Mitochondrial Disease; Development of Cortical Organoids to Model m.3243A>G Disease and Understand Cell Specificity; The Distribution and Functional Impact of MELAS Mutation m.3243A>G in Cardiac Cells, and Novel Approaches to Restore Cellular Dysfunction; Induced Pluripotent Stem Cell Based Cardiac Model of MELAS Disease; Modeling Diabetes in MELAS Disease Using Induced Pluripotent Stem Cell Based Parectatic Organoids

Mitochondrion and Immune System; Viral Exposures in Mito; Mito Dysfunction and COVID-19; Post-Acute Sequelae of COVID-19; Coronaviruses; Flaviviruses; Mito Disease & Viral Exposure; Connections Between Viral Exposome & Mito

Mitonuclear Signaling; PINK1- and Parkin-mediated Mitophagy & links to Inflammation & Neurodegeneration; Extracellular ATP Signaling, Inflammation, & Mitochondrial Dysfunction; Are Patients with Mitochondrial Diseases Hypermetabolic?